Verena Nordhoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Verena Nordhoff has a total of 276 co-authors. Here are the top co-authors by number of shared publications:
Sabine Kliesch
Department of Clinical and Surgical Andrology Centre of Reproductive Medicine and Andrology University Hospital of Münster Münster Germany
9 shared publications- Manuela Simoni
University of Modena and Reggio Emilia
7 shared publications - Sabine Kliesch
Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology, University Hospital Münster, Münster, Germany
7 shared publications - Stefan Schlatt
University Münster
7 shared publications - Andreas N. Schüring
UKM Kinderwunschzentrum, Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany
6 shared publications - Michele Boiani
Max Planck Institute for Molecular Biomedicine
5 shared publications
Latest Publications
- 2 August 2026
- Published by Springer Nature
- p. 309-318
Cryopreservation of Oocytes and Embryos
- 2 August 2026
- Published by Springer Nature
- p. 423-432
Cryopreservation of Testicular Tissue
- 2 August 2026
- Published by Springer Nature
- p. 413-422
Cryopreservation of Sperm
- Open Access
- 11 August 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (10) , 1829-1842
ESHRE’s key research priorities in infertility: maximizing impact on science, people and society
STUDY QUESTION: Which research topics in the area of infertility should be prioritized in the allocation of research resources? SUMMARY ANSWER: Twelve research priorities were formulated, spanning the following areas: preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments, optimizing psychosocial support and deepening knowledge on preimplantation development and early pregnancy. WHAT IS KNOWN ALREADY: Many research gaps related to infertility and its management remain understudied and underfunded, making it important to set priorities to ensure appropriate allocation of research resources. STUDY DESIGN, SIZE, DURATION: The European Society of Human Reproduction and Embryology (ESHRE) appointed a multidisciplinary working group, including a patient representative, to develop a list of research priorities related to infertility, which are relevant to researchers and institutions that fund research. PARTICIPANTS/MATERIALS, SETTING, METHODS: A list of research topics was collated based on the recommendations for future research formulated in ESHRE’s evidence-based guidelines and suggestions submitted by ESHRE’s Special Interest Groups as call topics for the ESHRE research grants. A scoring tool was developed to assess the expected impact of research on each topic on individuals, society and scientific advancement. Topics were scored independently by the working group members and the 12 topics with the highest scores were selected for presentation in this paper. MAIN RESULTS AND THE ROLE OF CHANCE: Using our newly developed scoring tool, we have identified 12 research priorities that broadly fall under six areas. These are preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments (two priorities per area selected), optimizing psychosocial support (one priority selected) and deepening knowledge on preimplantation development and early pregnancy (three priorities selected). LIMITATIONS, REASONS FOR CAUTION: The impact scoring tool would benefit from further testing and refinement in future projects. The scoring of some impact indicators is heavily based on the judgment and expertise of the scorers, which was accounted for by ensuring representation of knowledge and experience from all relevant disciplines and subject areas as well as the patient perspective within the working group. WIDER IMPLICATIONS OF THE FINDINGS: This paper may serve to stimulate further thought and discussion within the infertility research community on the potential impact of proposed and ongoing research. It will furthermore inform and encourage policy makers involved in research funding allocation and contribute to a more efficient and purposeful allocation of research resources towards infertility research. STUDY FUNDING/COMPETING INTEREST(S): The technical support for this project was provided by ESHRE. A.C. reports employment at Juno Genetics. Y.C. reports a grant from Guerbet and honoraria from Ferring, Merck, Abbot, Nordic Pharma and Organon. G.C. reports consulting fees from Gedeon Richter and honoraria from Cooper Surgical. S.G. reports the development of www.myjourney.pt licensed under a CC BY-NC-SA 4.0 licence. J.K.-B. reports grants from the NIHR Evaluation and Studies Coordinating Centre, the Gates Foundation, the Economic and Social Research Council, BAYER Consumer Health and MRC Confidence in Concept; honoraria from Ferring and Cooper Surgical; travel support from Ferring, Cooper Surgical, Congressworks LLP, Deutsche Gesellschaft für Andrologie e. V., BAYER, University of Munster and ESHRE; a patent for microchannel sperm cell preparation; and a leadership or fiduciary role in the Association of Clinical and Reproductive Scientists. A.P. reports grants (to her institution) and consulting fees from Gedeon Richter, Ferring, Merck A/S and Cryos; honoraria from Gedeon Richter, Ferring, Merck A/S and Organon; and travel support (to her institution) from Gedeon Richter. H.S.N. reports grants from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond and the Independent Research Fund Denmark; speaker’s fees from Ferring, Merck A/S, Astra Zeneca, Cook Medical, Gedeon Richter, Ibsa Nordic, Novo Nordisk A/S; co-development of an app with the Maternity Foundation; and co-founding a project with Lulu Health. The remaining authors (J.T., A.A., I.D., C.F., M.G., A.S.L., M.M.-R., V.N., A.O., N.R., M.S.-L., P.T., N.V., S.V. and K.S.) have nothing to declare. TRIAL REGISTRATION NUMBER: N/A
- 11 August 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (10) , 1829-1842
Open AccessESHRE’s key research priorities in infertility: maximizing impact on science, people and society
STUDY QUESTION: Which research topics in the area of infertility should be prioritized in the allocation of research resources? SUMMARY ANSWER: Twelve research priorities were formulated, spanning the following areas: preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments, optimizing psychosocial support and deepening knowledge on preimplantation development and early pregnancy. WHAT IS KNOWN ALREADY: Many research gaps related to infertility and its management remain understudied and underfunded, making it important to set priorities to ensure appropriate allocation of research resources. STUDY DESIGN, SIZE, DURATION: The European Society of Human Reproduction and Embryology (ESHRE) appointed a multidisciplinary working group, including a patient representative, to develop a list of research priorities related to infertility, which are relevant to researchers and institutions that fund research. PARTICIPANTS/MATERIALS, SETTING, METHODS: A list of research topics was collated based on the recommendations for future research formulated in ESHRE’s evidence-based guidelines and suggestions submitted by ESHRE’s Special Interest Groups as call topics for the ESHRE research grants. A scoring tool was developed to assess the expected impact of research on each topic on individuals, society and scientific advancement. Topics were scored independently by the working group members and the 12 topics with the highest scores were selected for presentation in this paper. MAIN RESULTS AND THE ROLE OF CHANCE: Using our newly developed scoring tool, we have identified 12 research priorities that broadly fall under six areas. These are preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments (two priorities per area selected), optimizing psychosocial support (one priority selected) and deepening knowledge on preimplantation development and early pregnancy (three priorities selected). LIMITATIONS, REASONS FOR CAUTION: The impact scoring tool would benefit from further testing and refinement in future projects. The scoring of some impact indicators is heavily based on the judgment and expertise of the scorers, which was accounted for by ensuring representation of knowledge and experience from all relevant disciplines and subject areas as well as the patient perspective within the working group. WIDER IMPLICATIONS OF THE FINDINGS: This paper may serve to stimulate further thought and discussion within the infertility research community on the potential impact of proposed and ongoing research. It will furthermore inform and encourage policy makers involved in research funding allocation and contribute to a more efficient and purposeful allocation of research resources towards infertility research. STUDY FUNDING/COMPETING INTEREST(S): The technical support for this project was provided by ESHRE. A.C. reports employment at Juno Genetics. Y.C. reports a grant from Guerbet and honoraria from Ferring, Merck, Abbot, Nordic Pharma and Organon. G.C. reports consulting fees from Gedeon Richter and honoraria from Cooper Surgical. S.G. reports the development of www.myjourney.pt licensed under a CC BY-NC-SA 4.0 licence. J.K.-B. reports grants from the NIHR Evaluation and Studies Coordinating Centre, the Gates Foundation, the Economic and Social Research Council, BAYER Consumer Health and MRC Confidence in Concept; honoraria from Ferring and Cooper Surgical; travel support from Ferring, Cooper Surgical, Congressworks LLP, Deutsche Gesellschaft für Andrologie e. V., BAYER, University of Munster and ESHRE; a patent for microchannel sperm cell preparation; and a leadership or fiduciary role in the Association of Clinical and Reproductive Scientists. A.P. reports grants (to her institution) and consulting fees from Gedeon Richter, Ferring, Merck A/S and Cryos; honoraria from Gedeon Richter, Ferring, Merck A/S and Organon; and travel support (to her institution) from Gedeon Richter. H.S.N. reports grants from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond and the Independent Research Fund Denmark; speaker’s fees from Ferring, Merck A/S, Astra Zeneca, Cook Medical, Gedeon Richter, Ibsa Nordic, Novo Nordisk A/S; co-development of an app with the Maternity Foundation; and co-founding a project with Lulu Health. The remaining authors (J.T., A.A., I.D., C.F., M.G., A.S.L., M.M.-R., V.N., A.O., N.R., M.S.-L., P.T., N.V., S.V. and K.S.) have nothing to declare. TRIAL REGISTRATION NUMBER: N/A
- Open Access
- 15 May 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (6) , 1417-1451
Genotype-specific differences in infertile men due to loss-of-function variants in M1AP or ZZS genes
Male infertility has been linked to M1AP. In mice, M1AP interacts with the ZZS proteins SHOC1/TEX11/SPO16, promoting DNA class I crossover formation during meiosis. To determine whether M1AP and ZZS proteins are involved in human male infertility by recombination failure, we screened for biallelic/hemizygous loss-of-function (LoF) variants in the human genes to select men with presumed protein deficiency ( N = 24). After in-depth characterisation of testicular phenotypes, we identified gene-specific meiotic impairments: men with ZZS deficiency shared an early meiotic arrest. Men with LoF variants in M1AP exhibited a predominant metaphase I arrest with rare haploid round or even elongated spermatids. These differences were explained by different recombination failures: deficient ZZS function led to incorrect synapsis of homologous chromosomes, unrepaired DNA double-strand breaks, and incomplete recombination. Abolished M1AP led to a reduced number of recombination intermediates and class I crossover. Medically assisted reproduction resulted in the birth of a healthy child, offering the possibility of fatherhood to men with LoF variants in M1AP . Our study establishes M1AP as an important, but non-essential, functional enhancer in meiotic recombination.
- 15 May 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (6) , 1417-1451
Open AccessGenotype-specific differences in infertile men due to loss-of-function variants in M1AP or ZZS genes
Male infertility has been linked to M1AP. In mice, M1AP interacts with the ZZS proteins SHOC1/TEX11/SPO16, promoting DNA class I crossover formation during meiosis. To determine whether M1AP and ZZS proteins are involved in human male infertility by recombination failure, we screened for biallelic/hemizygous loss-of-function (LoF) variants in the human genes to select men with presumed protein deficiency ( N = 24). After in-depth characterisation of testicular phenotypes, we identified gene-specific meiotic impairments: men with ZZS deficiency shared an early meiotic arrest. Men with LoF variants in M1AP exhibited a predominant metaphase I arrest with rare haploid round or even elongated spermatids. These differences were explained by different recombination failures: deficient ZZS function led to incorrect synapsis of homologous chromosomes, unrepaired DNA double-strand breaks, and incomplete recombination. Abolished M1AP led to a reduced number of recombination intermediates and class I crossover. Medically assisted reproduction resulted in the birth of a healthy child, offering the possibility of fatherhood to men with LoF variants in M1AP . Our study establishes M1AP as an important, but non-essential, functional enhancer in meiotic recombination.
- Open Access
Initial motility and vitality predict the semen quality after long‐term cryostorage, even in patients with restricted ejaculate parameters
Background: Cryopreservation of human semen is the cornerstone for preserving male fertility before gonadotoxic therapy or in cases of high variability in semen parameters. This is particular crucial in cases of severe oligoasthenoteratozoospermia (OAT), where diminished sperm counts may compromise planned intracytoplasmic sperm injection (ICSI) procedures. Previous investigations in donor programs have shown long‐term storage effects, such as decreased motility in cryopreserved semen samples. However, these studies were based on patients exhibiting normozoospermic semen samples. To date, there has been no comprehensive evaluation of the effect of long‐term cryostorage on sperm samples from individuals with compromised semen parameters. Objectives: The aim of this study was to identify the effect of long‐term cryostorage on semen parameters such as motility and vitality. Additionally, we sought to identify variables, which could aid in predicting motility and vitality following the freeze‐thaw process. Patients and methods: Within our center, we have archived sperm samples from 6022 patients cryopreserved between 2001 and 2019. Among these, 293 patients donated their samples for subsequent research following depot termination. We examined semen concentration, motility, morphology, and vitality of spermatozoa thawed after varying storage durations, alongside baseline metrics documented at the time of cryopreservation. Samples were stratified into three cohorts based on storage duration: 2.5 to ≤5 years, > 5 to ≤14 years, and > 14 years. Results: Our analysis revealed no changes in motility ( p = 0.44), vitality ( p = 0.08), or morphology ( p = 0.44) across the cohorts. Regression analysis demonstrated that initial motility and sperm concentration were significantly associated with post‐cryostorage motility, whereas storage duration was not ( p = 0.72). Similarly, there was no association between storage duration and post‐thaw value 2 vitality ( p = 0.64). Discussion: The initial semen analysis as well as the evaluation of a short‐term frozen sample immediately after cryopreservation, appeared to be the most important markers for predicting post‐thaw motility and vitality. Conclusion: Our results demonstrate the reliability of long‐term cryostorage of human spermatozoa for fertility preservation, even in individuals with constrained semen quality at the time of cryopreservation.
Open AccessInitial motility and vitality predict the semen quality after long‐term cryostorage, even in patients with restricted ejaculate parameters
Background: Cryopreservation of human semen is the cornerstone for preserving male fertility before gonadotoxic therapy or in cases of high variability in semen parameters. This is particular crucial in cases of severe oligoasthenoteratozoospermia (OAT), where diminished sperm counts may compromise planned intracytoplasmic sperm injection (ICSI) procedures. Previous investigations in donor programs have shown long‐term storage effects, such as decreased motility in cryopreserved semen samples. However, these studies were based on patients exhibiting normozoospermic semen samples. To date, there has been no comprehensive evaluation of the effect of long‐term cryostorage on sperm samples from individuals with compromised semen parameters. Objectives: The aim of this study was to identify the effect of long‐term cryostorage on semen parameters such as motility and vitality. Additionally, we sought to identify variables, which could aid in predicting motility and vitality following the freeze‐thaw process. Patients and methods: Within our center, we have archived sperm samples from 6022 patients cryopreserved between 2001 and 2019. Among these, 293 patients donated their samples for subsequent research following depot termination. We examined semen concentration, motility, morphology, and vitality of spermatozoa thawed after varying storage durations, alongside baseline metrics documented at the time of cryopreservation. Samples were stratified into three cohorts based on storage duration: 2.5 to ≤5 years, > 5 to ≤14 years, and > 14 years. Results: Our analysis revealed no changes in motility ( p = 0.44), vitality ( p = 0.08), or morphology ( p = 0.44) across the cohorts. Regression analysis demonstrated that initial motility and sperm concentration were significantly associated with post‐cryostorage motility, whereas storage duration was not ( p = 0.72). Similarly, there was no association between storage duration and post‐thaw value 2 vitality ( p = 0.64). Discussion: The initial semen analysis as well as the evaluation of a short‐term frozen sample immediately after cryopreservation, appeared to be the most important markers for predicting post‐thaw motility and vitality. Conclusion: Our results demonstrate the reliability of long‐term cryostorage of human spermatozoa for fertility preservation, even in individuals with constrained semen quality at the time of cryopreservation.
- 29 May 2024
- Published by Springer Nature
- p. 1-5
Fertilisierungsmöglichkeiten bei andrologischer Subfertilität
- 29 May 2024
- Published by Springer Nature
- p. 1-5
Fertilisierungsmöglichkeiten bei andrologischer Subfertilität
- Open Access
- 20 March 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13, e51145
Evaluation of the Gonadotoxicity of Cancer Therapies to Improve Counseling of Patients About Fertility and Fertility Preservation Measures: Protocol for a Retrospective Systematic Data Analysis and a Prospective Cohort Study
Background: Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients but may also have an impact on gonadal function and, therefore, on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment are very limited, this study was designed to fill this data gap. Objective: Primary objective of this study is to analyze the impact of cancer therapies and chemotherapies on the ovarian reserve and sperm quality. Secondary objectives are to analyze the (1) impact of cancer therapies and chemotherapies on other fertility parameters and (2) probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocols and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies. Methods: First, previously published studies on the gonadotoxicity of chemo- and radiotherapies among patients with cancer will be systematically analyzed. Second, a prospective cohort study set up by approximately 70 centers in Germany, Switzerland, and Austria will collect the following data: ovarian function by analyzing anti-Müllerian hormone (AMH) concentrations and testicular function by analyzing sperm parameters and total testosterone immediately before and around 1 year after gonadotoxic therapies (short-term fertility). A follow-up of these fertility parameters, including history of conceptions, will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility-preserving procedures, their satisfaction with these procedures, and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analyzed. Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be structured in accordance with the ICD (International Classification of Diseases) classification of cancer diseases and will be easily be accessible using a specific App. Results: Several funding bodies have funded this study. Ten systematic reviews are in progress and the first one has been accepted for publication. All Swiss and many German and Austrian ethics committees have provided their approval for the prospective cohort study. The study registry has been set up, and a study website has been created. In total, 50 infertility centers have already been prepared for data collection, which started on December 1, 2023. Conclusions: The study can be expected to bridge the data gap regarding the gonadotoxicity of cancer therapies to better counsel patients about their infertility risk and their need to undergo fertility preservation procedures. Initial data are expected to be uploaded on the FertiTOX platform in 2026. Trial Registration: ClinicalTrials.gov NCT05885048; https://clinicaltrials.gov/study/NCT05885048 International Registered Report Identifier (IRRID): DERR1-10.2196/51145
- 20 March 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13, e51145
Open AccessEvaluation of the Gonadotoxicity of Cancer Therapies to Improve Counseling of Patients About Fertility and Fertility Preservation Measures: Protocol for a Retrospective Systematic Data Analysis and a Prospective Cohort Study
Background: Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients but may also have an impact on gonadal function and, therefore, on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment are very limited, this study was designed to fill this data gap. Objective: Primary objective of this study is to analyze the impact of cancer therapies and chemotherapies on the ovarian reserve and sperm quality. Secondary objectives are to analyze the (1) impact of cancer therapies and chemotherapies on other fertility parameters and (2) probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocols and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies. Methods: First, previously published studies on the gonadotoxicity of chemo- and radiotherapies among patients with cancer will be systematically analyzed. Second, a prospective cohort study set up by approximately 70 centers in Germany, Switzerland, and Austria will collect the following data: ovarian function by analyzing anti-Müllerian hormone (AMH) concentrations and testicular function by analyzing sperm parameters and total testosterone immediately before and around 1 year after gonadotoxic therapies (short-term fertility). A follow-up of these fertility parameters, including history of conceptions, will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility-preserving procedures, their satisfaction with these procedures, and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analyzed. Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be structured in accordance with the ICD (International Classification of Diseases) classification of cancer diseases and will be easily be accessible using a specific App. Results: Several funding bodies have funded this study. Ten systematic reviews are in progress and the first one has been accepted for publication. All Swiss and many German and Austrian ethics committees have provided their approval for the prospective cohort study. The study registry has been set up, and a study website has been created. In total, 50 infertility centers have already been prepared for data collection, which started on December 1, 2023. Conclusions: The study can be expected to bridge the data gap regarding the gonadotoxicity of cancer therapies to better counsel patients about their infertility risk and their need to undergo fertility preservation procedures. Initial data are expected to be uploaded on the FertiTOX platform in 2026. Trial Registration: ClinicalTrials.gov NCT05885048; https://clinicaltrials.gov/study/NCT05885048 International Registered Report Identifier (IRRID): DERR1-10.2196/51145
- Top Cited PapersOpen Access
- 2 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (1)
Human fertilization in vivo and in vitro requires the CatSper channel to initiate sperm hyperactivation
The infertility of many couples rests on an enigmatic dysfunction of the man’s sperm. To gain insight into the underlying pathomechanisms, we assessed the function of the sperm-specific multisubunit CatSper-channel complex in the sperm of almost 2,300 men undergoing a fertility workup, using a simple motility-based test. We identified a group of men with normal semen parameters but defective CatSper function. These men or couples failed to conceive naturally and upon medically assisted reproduction via intrauterine insemination and in vitro fertilization. Intracytoplasmic sperm injection (ICSI) was, ultimately, required to conceive a child. We revealed that the defective CatSper function was caused by variations in CATSPER genes. Moreover, we unveiled that CatSper-deficient human sperm were unable to undergo hyperactive motility and, therefore, failed to penetrate the egg coat. Thus, our study provides the experimental evidence that sperm hyperactivation is required for human fertilization, explaining the infertility of CatSper-deficient men and the need of ICSI for medically assisted reproduction. Finally, our study also revealed that defective CatSper function and ensuing failure to hyperactivate represents the most common cause of unexplained male infertility known thus far and that this sperm channelopathy can readily be diagnosed, enabling future evidence-based treatment of affected couples.
- 2 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (1)
Top Cited PapersOpen AccessHuman fertilization in vivo and in vitro requires the CatSper channel to initiate sperm hyperactivation
The infertility of many couples rests on an enigmatic dysfunction of the man’s sperm. To gain insight into the underlying pathomechanisms, we assessed the function of the sperm-specific multisubunit CatSper-channel complex in the sperm of almost 2,300 men undergoing a fertility workup, using a simple motility-based test. We identified a group of men with normal semen parameters but defective CatSper function. These men or couples failed to conceive naturally and upon medically assisted reproduction via intrauterine insemination and in vitro fertilization. Intracytoplasmic sperm injection (ICSI) was, ultimately, required to conceive a child. We revealed that the defective CatSper function was caused by variations in CATSPER genes. Moreover, we unveiled that CatSper-deficient human sperm were unable to undergo hyperactive motility and, therefore, failed to penetrate the egg coat. Thus, our study provides the experimental evidence that sperm hyperactivation is required for human fertilization, explaining the infertility of CatSper-deficient men and the need of ICSI for medically assisted reproduction. Finally, our study also revealed that defective CatSper function and ensuing failure to hyperactivate represents the most common cause of unexplained male infertility known thus far and that this sperm channelopathy can readily be diagnosed, enabling future evidence-based treatment of affected couples.
- 27 October 2023
- Published by Springer Nature
- p. 165-180
Sperm Quality and Sperm Function Tests